Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 39Neoplasms 6Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms, Castration-Resistant 3Metastatic Castration-Resistant Prostate Cancer 3Colorectal Neoplasms 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Melanoma 2Carcinoma, Hepatocellular 2Bulbo-Spinal Atrophy, X-Linked 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Prostatic Diseases 1Primary Myelofibrosis 1Pancreatic Neoplasms 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1

Interventions

enzalutamide 5abiraterone 3Prednisone 3Docetaxel 3Abiraterone Acetate 3relugolix 1pembrolizumab 1onvansertib 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1abemaciclib 1Prednisolone 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-Resistant Prostate Cancer × abiraterone × Clear all
NCT07287150 2026-06-04

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Cardiff Oncology

Phase 2 Completed
72 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡